Comparative Pharmacology
Head-to-head clinical analysis: AMINOSYN HBC 7 IN PLASTIC CONTAINER versus PROSOL 20 SULFITE FREE IN PLASTIC CONTAINER.
Peer-Reviewed Evidence
Head-to-head clinical analysis: AMINOSYN HBC 7 IN PLASTIC CONTAINER versus PROSOL 20 SULFITE FREE IN PLASTIC CONTAINER.
AMINOSYN-HBC 7% IN PLASTIC CONTAINER vs PROSOL 20% SULFITE FREE IN PLASTIC CONTAINER
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Provides essential and nonessential amino acids to support protein synthesis and nitrogen balance in patients with metabolic stress or hepatic encephalopathy.
Propofol is a short-acting intravenous anesthetic agent that potentiates GABA-A receptor activity, resulting in rapid loss of consciousness through inhibition of neuronal firing in the central nervous system.
1-2 L/day intravenously (equivalent to 70-140 g amino acids/day) for adults; infuse at no more than 0.1 g/kg/h.
Intravenous infusion: 20 mL/kg (4 g/kg) as a 20% solution administered over 2-4 hours. May repeat up to 100 mL/kg/day if needed.
None Documented
None Documented
Terminal elimination half-life of infused amino acids is approximately 0.5-1 hour for free amino acids, but varies by individual amino acid. Clinical context: rapid clearance in critically ill patients due to increased metabolic demand.
Terminal elimination half-life is approximately 1–2 hours in healthy individuals; may be prolonged in renal impairment due to accumulation of metabolites.
Renal: 100% of infused amino acids are metabolized or excreted renally as urea and other nitrogenous waste products. No biliary or fecal elimination.
Renal excretion of unchanged drug is minimal (<5%). The majority is metabolized via the tricarboxylic acid cycle to CO2 and water. Biliary/fecal elimination is negligible.
Category C
Category C
Parenteral Nutrition Solution
Parenteral Nutrition Solution